Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.

Abstract

OBJECTIVE:

To compare longitudinal metabolic effects of 7 antipsychotics, including body mass index (BMI), waist circumference (WC), blood pressure (BP), glucose, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C); to investigate risk factors for metabolic syndrome (MetS); and to make recommendations on frequency and timing of monitoring metabolic measurements.

METHODS:

This randomized, open-label, pharmacologic trial was conducted among patients with schizophrenia (DSM-IV) in 32 hospitals across China. Patients were randomly assigned to 7 groups and assessed at baseline, 2, 4, and 6 weeks. Linear mixed-effect models were used to assess changes of metabolic measures over time. Multivariable logistic regression analysis was performed to investigate the risk factors for MetS.

RESULTS:

In total, 2,550 (718 drug-naïve) of 2,774 patients finished the study between July 6, 2010, and November 30, 2011. We found significant (P < .05) changes for BMI, WC, TG, and LDL-C, with TG and LDL-C reaching a plateau. Interactions between baseline metabolic condition and changes over time were observed for BMI (χ² = 43.11, P < .001), WC (χ² = 36.34, P < .001), systolic BP (χ² = 11.92, P = .002), glucose (χ² = 6.09, P = .01), and TG (χ² = 6.01, P = .01). Antipsychotics generally had greater adverse effects on patients who were initially screened as metabolically normal. After controlling for other associated factors, we found that antipsychotics resulted in differing risk for incident MetS, with a similar pattern to findings in other populations: olanzapine (odds ratio [OR] = 3.36, P < .001) > quetiapine (OR = 3.29, P < .001) > perphenazine (OR = 2.73, P = .007) > risperidone (OR = 2.21, P = .02) > aripiprazole (OR = 1.74, P = .15) ≈ haloperidol (OR = 1.75, P = .22) ≈ ziprasidone (OR = 1, reference).

CONCLUSIONS:

Metabolic traits should be monitored frequently in early stages of antipsychotic treatment due to rapid and substantial changes. Clinicians should not assume low risk for patients with normal metabolic parameters at baseline.

TRIAL REGISTRATION:

Chinese Clinical Trial Registry identifier: ChiCTR-TRC-10000934.

• Authors: Yamin Zhang, Qiang Wang, Gavin P Reynolds, Weihua Yue, Wei Deng, Hao Yan, Liwen Tan, Chuanyue Wang, Guigang Yang, Tianlan Lu, Lifang Wang, Fuquan Zhang, Jianli Yang, Keqing Li, Luxian Lv, Qingrong Tan, Yinfei Li, Hua Yu, Hongyan Zhang, Xin Ma, Fude Yang, Lingjiang Li, Qi Chen, Wei Wei, Liansheng Zhao, Huiyao Wang, Xiaojing Li, Wanjun Guo, Xun Hu, Yang Tian, Hongyan Ren, Xiaohong Ma, Jeremy Coid, Dai Zhang, Tao Li, Chinese Antipsychotics Pharmacogenomics Consortium
• Journal: The Journal of clinical psychiatry (J Clin Psychiatry) Vol. 81 Issue 3 (03 24 2020) ISSN: 1555-2101 [Electronic] United States
• PMID: 32237292 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © Copyright 2020 Physicians Postgraduate Press, Inc.

Chemical References

• Antipsychotic Agents
• Blood Glucose
• Cholesterol, HDL
• Cholesterol, LDL
• Piperazines
• Thiazoles
• Triglycerides
• Quetiapine Fumarate
• ziprasidone
• Aripiprazole
• Risperidone
• Olanzapine

Topics

• Adult
• Antipsychotic Agents (adverse effects, therapeutic use)
• Aripiprazole (adverse effects, therapeutic use)
• Blood Glucose (drug effects)
• Cholesterol, HDL (blood)
• Cholesterol, LDL (blood)
• Female
• Humans
• Male
• Metabolic Syndrome (chemically induced)
• Olanzapine (adverse effects, therapeutic use)
• Piperazines (adverse effects, therapeutic use)
• Quetiapine Fumarate (adverse effects, therapeutic use)
• Risk Factors
• Risperidone (adverse effects, therapeutic use)
• Schizophrenia (drug therapy, metabolism)
• Thiazoles (adverse effects, therapeutic use)
• Triglycerides (blood)